Tocilizumab Prophylaxis Following Idecabtagene Vicleucel in the Outpatient Setting in Patients with Relapsed or Refractory Multiple Myeloma

Key Points

• Tocilizumab prophylaxis correlates with enhanced treatment outcomes in multiple myeloma.
• A significant improvement in adverse events was noted compared to historical controls.
• Observational analysis shows the use of tocilizumab following idecabtagene vicleucel in an outpatient setting.
• Findings may support expanded use of tocilizumab in treatment protocols for multiple myeloma.